Ideaya Biosciences, Inc.
Ideaya Biosciences, Inc. is listed today as IDEAYA Biosciences, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2018 | $94 M | No. 2 | $50 to $250 million | equity | SEC | |
| Mar 2016 | $17 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Ideaya Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (May 2018).
SEC Form D · May 2018
The industry group it chose in its notices: Other.
SEC Form D · May 2018
That is all the official record says: Ideaya Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Ideaya Biosciences, Inc. are on record.
Investors#
6 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| 5AM Co-Investors IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| 5AM Partners IV, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| 5AM Ventures IV, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Alexandria Venture Investments, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Canaan Partners X LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Canaan X L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 23 investors.
Largest shareholders today
Institutions holding IDEAYA Biosciences, Inc. shares, as of Sep 30, 2026.
- FMR LLC$556 M14.97%
- BlackRock, Inc.$367 M9.87%
- Janus Henderson Group Ltd.$331 M8.92%
- Capital Research Global Investors$205 M5.52%
- Baker Bros. Advisors LP$192 M5.18%
- Vanguard Capital Management LLC$166 M4.46%
- State Street Corp$151 M4.06%
- Logos Global Management LP$109 M2.95%
- Adage Capital Partners GP, L.L.C.$104 M2.81%
- Geode Capital Management, LLC$98 M2.63%
- Price T Rowe Associates Inc /MD/$82 M2.21%
- Deerfield Management Company, L.P.$77 M2.07%
- Morgan Stanley$74 M1.99%
- Dimensional Fund Advisors LP$66 M1.78%
- Alliancebernstein L.P.$59 M1.59%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jeffrey P. Hager | Executive officer | May 2018 |
| Michael P. Dillon | Executive officer | May 2018 |
| Paul A. Stone | Executive officer | May 2018 |
| Tim P. Smith | Executive officer | May 2018 |
| Yujiro S. Hata | Executive officer | May 2018 |
| Paul Stone | Executive officer | Aug 2016 |
| Yujiro Hata | Executive officer | Aug 2016 |
| Brian Daniels | Director | May 2018 |
| Edward P. Hu | Director | May 2018 |
| Jeffrey S. Stein | Director | May 2018 |
| John D. Diekman | Director | May 2018 |
| Terry S. Rosen | Director | May 2018 |
| Thilo P. Schroeder | Director | May 2018 |
| Timothy S. Shannon | Director | May 2018 |
| Yujiro S. Hata | Director | May 2018 |
| Jeffrey Stein | Director | Aug 2016 |
| John Diekman | Director | Aug 2016 |
| Terry Rosen | Director | Aug 2016 |
| Timothy Shannon | Director | Aug 2016 |
| Yujiro Hata | Director | Aug 2016 |
About
Company in South San Francisco, United States.
Went public since 2019. Its SEC number is that of a company listed on a stock exchange.